A week after presenting compelling Lynparza (olaparib) results in prostate cancer, AstraZeneca (LSE: AZN) and Merck & Co (NYSE: MRK) have completed the data set in support of its use across advanced ovarian cancer disease maintenance settings.
The companies, which are co-developing and co-commercializing Lynparza, on Wednesday announced positive results from the Phase III PAOLA-1 trial in women with advanced ovarian cancer.
This study, in the first-line maintenance setting, compared Lynparza in combination with the standard-of-care (SoC) treatment bevacizumab, versus the latter drug alone, in women with or without BRCA gene mutations.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze